NMC Advisory on Stem Cell Therapy for Autism: Key Guidelines and Implications

Learn about the NMC advisory on stem cell therapy for autism, its legality, safety concerns, and impact on medical practice in India.

Context: The National Medical Commission (NMC) has directed medical practitioners and clinics not to use stem cell therapy for treating autism

Autism Spectrum Disorder (ASD)

Definition: Autism Spectrum Disorder is characterised by deficits in social communication and restricted/repetitive behaviours.
Onset: Symptoms typically appear before age 3 and persist throughout life.
Prevalence: ~1 in 100 children globally (WHO); significantly increasing diagnosis rates worldwide.
Etiology: Strong genetic basis with contributions from early brain development and environmental factors; not caused by vaccines.
Key features: Impaired social interaction, delayed language development, repetitive movements, restricted interests and sensory sensitivities.
Diagnosis: Based on behavioural and developmental assessments, not laboratory tests.
Management: No cure, but early intervention (e.g., speech therapy, behavioural therapy) can greatly improve outcomes.
- Support in education, social skills training, and sometimes medications for associated symptoms (like anxiety or hyperactivity).
Stem cell therapy (India): Not approved for routine treatment; classified as investigational under the National Guidelines for Stem Cell Research.
Global Awareness: April 2 is observed as World Autism Awareness Day.

Reasons for NMC Advisory

Supreme Court direction: The advisory follows a judgment in the case involving Yash Charitable Trust vs Union of India, where the court highlighted the lack of scientific evidence supporting stem cell therapy for autism.
ICMR recommendation: Following the ruling, the Indian Council of Medical Research wrote to the NMC asking it to circulate an advisory to ensure compliance with the judgment and national stem-cell guidelines
Protection of patients: The National Medical Commission issued the advisory to prevent unsafe, costly and unproven treatments being offered to vulnerable families.

Regulatory Framework of Stem Cell Use

Stem cell use in India is governed by the National Guidelines for Stem Cell Research (NGSCR) issued by the Indian Council of Medical Research and the Department of Biotechnology. It broadly classifies stem cell use in humans into two categories:

Approved clinical use (32 diseases)(given in Annex use of NGSCR): Routine clinical use of stem cell therapy is permitted for about 32 approved indications, mainly blood cancers and severe blood disorders treated through hematopoietic stem cell transplantation (HSCT) (e.g., leukaemia, thalassemia, aplastic anaemia, multiple myeloma).
Other diseases (research only): For conditions outside this list—including Autism Spectrum Disorder—stem cell therapy cannot be used as routine treatment and is allowed only within regulated clinical research.

Regulatory Framework for Stem Cell Research

Institutional oversight: Research must be approved by the Institutional Committee for Stem Cell Research (IC-SCR) and the Institutional Ethics Committee (IEC).
- Both committees must be registered with national regulatory authorities.
Regulatory approval: Depending on the type of stem cell trials:
- Central Drugs Standard Control Organisation regulates clinical trials involving extensively manipulated stem cells.
- Department of Health Research (DHR) oversees minimally manipulated stem cell therapies.

Research infrastructure and qualifications

Clinical trials must be conducted only at Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) certified facilities, and led by qualified medical professionals registered with the National Medical Commission (earlier Medical Council of India).